Zentiva Romania (former Sicomed) witnessed sales worth 38.4 million euros in the first six months of this year, a 14-fold increase against the similar period of last year, according to the six-month report of the Czech group Zentiva. Not taking into consideration the sales of the Sicomed producer, taken over last year by Zentiva, the portfolio made up of drugs of the Czech company totalled sales worth some 23 million euros, representing an almost eight-fold increase against the first six months of 2005.
"The growth was generated by the fact that an optimal development strategy was implemented, as well as by our launching new products (Tralgit, Fokusin, Coxtral) on the Romanian market, which generated large sales to the company. The sales trend was also stimulated by Simvacard, a product whose sales in Romania exceed 50% of its total sales," stated Mariana Wencz, country manager at Zentiva.
In terms of international Zentiva brands, the best selling drugs on the local market were Simvacard and Tralgit, 54% more than last year. However, it was local brands, like Algocalmin, Antinevralgic P, Extraveral and Dicarbocalm that contributed the most to the results achieved in Romania.
As a matter of fact, Algocalmin became one of the best selling drugs of the Czech group at an international level, ranking 6th among its products, with sales worth 6.3 million euros.
"In Romania, which is now the second largest market for Zentiva, we will continue to strengthen our presence by launching increasingly more successful brands and we expect this positive trend to maintain in the future, as well," stated Zentiva's chairman, Jir? Michal.
On the other hand, Klaas Postema, general manager of pharmaceutical maker Zentiva SA Romania gave up this position yesterday, but will remain chairman of the company's Board of Directors.
"Until the appointment of a
